Södertälje, Sweden

Karol Horvath

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 1.8

ph-index = 2

Forward Citations = 77(Granted Patents)


Location History:

  • Sodertalje, SE (2000)
  • Södertälje, SE (2001 - 2015)

Company Filing History:


Years Active: 2000-2015

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Karol Horvath: Innovator in Pharmaceutical Chemistry

Introduction

Karol Horvath is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds and their crystalline forms. With a total of 7 patents to his name, Horvath's work has had a considerable impact on drug formulation and delivery.

Latest Patents

Among his latest patents, Horvath has developed a hemihydrate form of the sodium salt of pemirolast. This innovation is crucial for enhancing the stability and efficacy of the compound. Additionally, he has discovered a novel crystal form of leukotriene B, specifically the 5S,12R-dihydroxy-6,8,10,14(Z,E,E,Z)-eicosatetraenoic acid. This twenty-carbon tetra-unsaturated fatty acid is significant as no crystal forms of leukotriene B were previously known in the art.

Career Highlights

Throughout his career, Karol Horvath has worked with prominent companies in the pharmaceutical industry, including AstraZeneca AB and Astra Aktiebolag. His expertise in crystallography and drug formulation has positioned him as a key player in the development of new therapeutic agents.

Collaborations

Horvath has collaborated with esteemed colleagues such as Martin Hans Bohlin and Bo Lindqvist. These partnerships have fostered innovation and have been instrumental in advancing his research and patent portfolio.

Conclusion

Karol Horvath's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in drug development and formulation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…